When was Spyre Therapeutics founded?

Spyre Therapeutics was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is Spyre Therapeutics located?

Spyre Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of Spyre Therapeutics?

Cameron Turtle of Spyre Therapeutics.

How many employees does Spyre Therapeutics have?

As of Mar 31, 2026, the latest employee count at Spyre Therapeutics is 108.

Is Spyre Therapeutics a funded company?

Spyre Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Dec 07, 2023.

When was the latest funding round of Spyre Therapeutics?

Spyre Therapeutics' latest funding was a $***** Post IPO round on Dec 07, 2023, with participation from 14 investors.

What is the annual revenue of Spyre Therapeutics?

Annual revenue of Spyre Therapeutics is $886K as on Dec 31, 2023.

Where does Spyre Therapeutics rank among its competitors?

Spyre Therapeutics ranks 59th amongst 155 active competitors, of which 66 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tubulis Technologies, which secured $401M in Oct, 2025.

Who are the top competitors of Spyre Therapeutics?

Spyre Therapeutics' top competitors include Dren Bio, PureTech Health and Protagonist Therapeutics. Among them, Tubulis Technologies secured the most recent funding round in October, 2025.

Spyre Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Spyre Therapeutics is a public company based in San Francisco (United States), founded in 2023. It operates as a Developer of monoclonal antibody therapeutics for inflammatory bowel disease. Spyre Therapeutics has raised an undisclosed amount in funding. The company has 155 active competitors, including 66 funded and 35 that have exited. Its top competitors include companies like Dren Bio, PureTech Health and Protagonist Therapeutics.

Company Details

Developer of monoclonal antibody therapeutics for inflammatory bowel disease. The company combines best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to develop pipeline of antibody therapies targeting α4B7, TL1A, and IL-23 for the treatment of inflammatory bowel disease.

Website: www.spyre.com/
Social
Email ID: *****@spyre.com

Key Metrics

Founded Year

2023

Location

San Francisco, United States

Stage

Public

Latest Funding Round

Post IPO, Dec 07, 2023, $*****

Investors

Aisling Capital & 14 more

Ranked

59^th among 155 active competitors

Annual Revenue

$886K as on Dec 31, 2023

Employee Count

108 as on Mar 31, 2026

Similar Companies

Dren Bio & 167 more

Exit Details

Public

View Spyre Therapeutics' full profile

Spyre Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Spyre Therapeutics, Inc. CIN: 1636282 , United States, Active	Jan 03, 2024	$886K (As on Dec 31, 2023)	30 (As on Dec 31, 2023)	-

Spyre Therapeutics got listed on Apr 07, 2016.

Click here to take a look at Spyre Therapeutics's IPO in detail

Spyre Therapeutics has raised funding over 1 round. Its latest funding round was a Post IPO round on Dec 07, 2023 for $*****. 14 investors participated in its latest round. Spyre Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of Spyre Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 07, 2023	7239505	Post IPO	1874901	8067210	1976723	3597819

Access funding benchmarks and valuations. Sign up today!

View details of Spyre Therapeutics's funding rounds and investors

Spyre Therapeutics' employee count trend

Spyre Therapeutics has 108 employees as of Mar 26. Here is Spyre Therapeutics's employee count trend over the years:

Employee count trend for Spyre Therapeutics

Uncover Spyre Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Spyre Therapeutics include Dren Bio, PureTech Health and Protagonist Therapeutics. Here is the list of Top 10 competitors of Spyre Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Dren Bio 2019, San Carlos (United States), Series B	Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases	$156M	Aisling Capital, 8VC & 13 others	69/100
2nd	PureTech Health 2001, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual	67/100
3rd	Protagonist Therapeutics 2001, Milpitas (United States), Public	Developer of oral peptide therapeutics for gastrointestinal diseases	$67M	Lilly Ventures, Canaan & 12 others	67/100
4th	Adagene 2012, Suzhou (China), Public	Developer of immunotherapy for the treatment of cancer	$155M	F-Prime Capital, Eight Roads Ventures & 12 others	67/100
5th	STAR Therapeutics 2018, San Francisco (United States), Series D	Developer of antibody therapies for multiple diseases	$215M	Sofinnova Investments, Viking Global Investors ... & 17 others	66/100
6th	Tubulis Technologies 2015, Munich (Germany), Series C	Developer of antibody-drug conjugates for the treatment of cancer	$615M	Life Sciences Partners, Venrock & 27 others	64/100
7th	Shattuck Labs 2016, Austin (United States), Public	Developer of an immunotherapy platform for oncology and other diseases	$165M	Redmile Group, Orbimed & 13 others	64/100
8th	Samsung Bioepis 2012, Incheon (South Korea), Acquired	Developer of biosimilar drugs for the treatment of multiple diseases	-	Biogen, Samsung BioLogics	64/100
9th	ARS Pharmaceuticals 2018, San Diego (United States), Public	Developer of therapeutics for the treatment of allergic reactions	$75M	Deerfield, SR One & 3 others	62/100
10th	Auron Therapeutics 2018, Wellesley (United States), Series B	Developer of cancer therapeutics for the treatment of blood cancer	$118M	Mubadala, Polaris Partners & 11 others	62/100
59th	Spyre Therapeutics 2023, San Francisco (United States), Public	Developer of monoclonal antibody therapeutics for inflammatory bowel disease	-	Aisling Capital, Boxer Capital & 13 others	48/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Spyre Therapeutics's competitors? Click here to see the top ones

Spyre Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Spyre Therapeutics's sector:

Free

Gastroenterology - Sector Report

Edition: November, 2025 (69 Pages)

View all reports related to Spyre Therapeutics

Media has covered Spyre Therapeutics for a total of 29 events in the last 1 year, 17 of them have been about company updates and 3 about people movement.